Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 10:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2737–2760 of 4,253 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Study Product Clear all

Conditions: Central Centrifugal Cicatricial Alopecia
Interventions: Calcipotriol, Subject's already prescribed drug; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Pulmonary Hypertension
Interventions: Iloprost PD-6, Iloprost PD-15; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 12
States / cities: Phoenix, Arizona • La Jolla, California • Iowa City, Iowa + 8 more

Conditions: Breast Cancer
Interventions: Paclitaxel, BKM120 matching placebo, BKM120; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 21
States / cities: Chandler, Arizona • Phoenix, Arizona • Fayetteville, Arkansas + 17 more

Conditions: Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions: anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT; Biological · Drug · Procedure
Lead sponsor: Northside Hospital, Inc.; Other
Eligibility: Up to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Diabetes Mellitus
Interventions: Alogliptin and metformin, Metformin; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 527 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 40
States / cities: Phoenix, Arizona • Anaheim, California • Artesia, California + 37 more

Conditions: HIV Infections
Interventions: BMS-663068, Placebo; Drug · Other
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 371 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 39
States / cities: Los Angeles, California • Palm Springs, California • San Francisco, California + 27 more

Conditions: Aging, Sedentary Lifestyle, Frailty
Interventions: Placebos, 20mg sodium nitrite tid; Drug
Lead sponsor: Gladwin, Mark, MD; Individual
Eligibility: 70 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hypertension
Interventions: Intensive control of SBP, Standard control of SBP; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 50 Years and older
Enrollment: 9,361 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2019
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Obesity and Overweight, Insulin Resistance, Obesity and Obesity-related Medical Conditions
Interventions: Lactulose Oral Product; Other
Lead sponsor: Yale University; Other
Eligibility: 15 Years to 22 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Stroke
Interventions: hyaluronidase plus saline, saline; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pain
Interventions: Relief Product Placebo Control, Relief Active Product 1, Relief Active Product 2, Relief Active Product 3; Dietary Supplement
Lead sponsor: Radicle Science; Industry
Eligibility: 21 Years to 105 Years
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Del Mar, California

Conditions: Healthy
Interventions: Mimio Study Product, Placebo; Dietary Supplement
Lead sponsor: Mimio Health, Inc.; Industry
Eligibility: 55 Years and older
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Respiratory Insufficiency
Interventions: Vibrating Mesh Nebulizer Arm, Jet Nebulizer Arm; Device
Lead sponsor: Rush University Medical Center; Other
Eligibility: 1 Year and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: ACS - Acute Coronary Syndrome
Interventions: MT1002 for Injection; Drug
Lead sponsor: Shaanxi Micot Pharmaceutical Technology Co., Ltd.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Depression
Interventions: W-GenZD Mobile Application, Digital Education Application (W-EdZD); Device
Lead sponsor: Woebot Health; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Diabetes Mellitus
Interventions: AMG 876; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 6
States / cities: Chula Vista, California • Miramar, Florida • Overland Park, Kansas + 3 more

Conditions: Feeding Behavior, Feeding Disorder of Infancy or Early Childhood
Interventions: Megestrol Acetate, iKanEat Behavioral Intervention; Drug · Behavioral
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 9 Months to 108 Months
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2025
U.S. locations: 8
States / cities: San Diego, California • Orlando, Florida • Indianapolis, Indiana + 5 more

Conditions: Rheumatoid Arthritis
Interventions: fostamatinib, placebo, fostamatinib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 913 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 57
States / cities: Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 54 more

Conditions: Heartburn
Interventions: Calcium carbonate/magnesium hydroxide/Lansoprazole 15 mg, Lansoprazole, Calcium carbonate/magnesium hydroxide, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Pregnancy, Preeclampsia (PE)
Interventions: 17 OHPC; Drug
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Breast Cancer Risk
Interventions: Breast Cancer Risk Reduction Household Intervention; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 10 Years to 65 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypoxia, Hypercapnia
Interventions: L-NMMA, Ketorolac, Ascorbic Acid, Intravenous Catheter, Transcranial Doppler Ultrasound; Drug · Procedure
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 45 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Anxiety, Stress
Interventions: Radicle Calm Study Placebo Control 1, Radicle Calm Study Placebo Control 2, Radicle Calm Study Active Product 1.1, Radicle Calm Study Active Product 2.1, Radicle Calm Study Active Product 2.2; Dietary Supplement
Lead sponsor: Radicle Science; Industry
Eligibility: 21 Years to 105 Years
Enrollment: 1,211 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Del Mar, California

Conditions: Menkes Disease
Interventions: Droxidopa Oral Product, Placebo Control; Drug · Other
Lead sponsor: Stephen G. Kaler; Other
Eligibility: 7 Years to 17 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Calcipotriol as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA)

The "Power 15 Study": Safety Study of Inhalation of Ventavis With the Power Disc-15 Setting

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

Efficacy and Safety of Alogliptin Combined With Metformin in Participants With Type 2 Diabetes Mellitus

Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients

Nitrites, Skeletal Muscle Mitochondrial Bioenergetics, and Physical Activity in Old Age

Systolic Blood Pressure Intervention Trial

New Mechanisms of Obesity

Myofascial Dysfunction in Post Stroke Shoulder Pain

Radicle Relief 24_RLN: A Study Assessing the Impact of Health and Wellness Products on Pain and Related Health Outcomes.

Observational Metabolic Health Study

RCT of Mesh Versus Jet Nebulizers on Clinical Outcomes During Mechanical Ventilation in the Intensive Care Unit

Evaluate the Effects of Renal Impairment on the Pharmacokinetics and Pharmacodynamics

Digital Therapeutic vs Educational App for Depression Among Adolescents

Multiple Ascending Dose Study in Subjects With Type 2 Diabetes

iKanEat: A Randomized-controlled, Multi-center Trial of Megestrol for Chronic Oral Food Refusal in Children

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.

Proof of Concept Study Efficacy of an Antacid/Lansoprazole Combination for Relief of Heartburn

Progesterone to Enhance the Efficacy and Success of Expectantly Managed Preterm Severe/Superimposed Preeclampsia

Family-Based Intervention Study of the Effects of Environmental Exposures on Breast Tissue Composition

Impact of NOS, COX, and ROS Inhibition on Cerebral Blood Flow Regulation

Radicle Calm 1: A Study of Health and Wellness Products on Feelings of Anxiety, Stress and Other Health Outcomes

NORTHERA (DROXIDOPA) for Dysautonomia in Pediatric Survivors of Menkes Disease